CEACAM5 and neoplasm: While whole tumor vaccines have shown limited efficacy due to poor immunogenicity, peptide antigen vaccines targeting CEA or mucin-1 have demonstrated positive trends in clinical trials, albeit with HLA-restricted applicability [124].